|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9232
|
|
pubmed:dateCreated |
2000-10-19
|
|
pubmed:abstractText |
Postsurgical recurrence of hepatocellular carcinoma (HCC) is frequent and fatal. Adoptive immunotherapy is active against HCC. We assessed whether postoperative immunotherapy could lower the frequency of recurrence.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
pubmed-author:HirohashiSS,
pubmed-author:KakizoeTT,
pubmed-author:KosugeTT,
pubmed-author:MakuuchiMM,
pubmed-author:OhashiYY,
pubmed-author:SakamotoMM,
pubmed-author:SekineTT,
pubmed-author:ShimadaKK,
pubmed-author:TakayamaTT,
pubmed-author:YamamotoJJ,
pubmed-author:YamasakiSS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
2
|
|
pubmed:volume |
356
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
802-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11022927-Adult,
pubmed-meshheading:11022927-Aged,
pubmed-meshheading:11022927-Aged, 80 and over,
pubmed-meshheading:11022927-Carcinoma, Hepatocellular,
pubmed-meshheading:11022927-Disease-Free Survival,
pubmed-meshheading:11022927-Hepatectomy,
pubmed-meshheading:11022927-Humans,
pubmed-meshheading:11022927-Immunotherapy,
pubmed-meshheading:11022927-Interleukin-2,
pubmed-meshheading:11022927-Liver Neoplasms,
pubmed-meshheading:11022927-Middle Aged,
pubmed-meshheading:11022927-Neoplasm Recurrence, Local,
pubmed-meshheading:11022927-Postoperative Period
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
|
|
pubmed:affiliation |
Department of Surgery, National Cancer Centre Research Institute, University of Tokyo, Japan. takayamat-2su@h.u-tokyo.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
